3月4日，据CDE官网消息，杭州博之锐生物制药有限公司、浙江博锐生物制药有限公司联合申请药品“注射用BR111”，获得临床试验默示许可，受理号CXSL2400885。
公示信息显示，药品“注射用BR111”适应症：晚期恶性肿瘤。
杭州博之锐生物制药有限公司，成立于2010年，位于杭州市，是一家以从事医药制造业为主的企业。企业注册资本75000万人民币，实缴资本75000万人民币。
通过天眼查大数据分析，杭州博之锐生物制药有限公司参与招投标项目279次，知识产权方面有商标信息4条，专利信息37条，此外企业还拥有行政许可32个。
主要股东信息显示，杭州博之锐生物制药有限公司由浙江博锐生物制药有限公司持股100%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.